The 21st Century has witnessed the publication of a series of medical journals, and one of the most notable journals of this kind is Oncotarget. With Impact Journals as its official publisher, this remarkable journal was established in 2010 with the aim of proffering to its readers an exclusive explanation and insights regarding the field of Oncology, the scientific study and treatment of tumours.Other than being an open-access journal that is available to the public at large, Oncotarget remains an outstanding journal as it is reviewed on weekly intervals by their proficient team of editors such as Mikhail Blagosklonny. Oncotarget’s exceptional insightfulness in the medical realm, especially in respect of treating tumours, was exemplified in an article authored by Wang-Yang Pu, entitled ‘Prediction of Cancer Progression in a Group of 73 Gastric Cancer Patients by circulating cell-free DNA.’
Bearing in mind the fact that gastric cancer is one of the most prevalent cancers, this article envisaged highlighting the process of circulating cell-free DNA within the human anatomy in order to predict gastric cancer progression rate therein. This prediction is premised on the fact that circulating cell-free DNA located in the plasma may contain some specific tumour makers and the fact that circulating cell-free DNA is an effective detector and predictor for malignant tumours in the human body.The article begins by enumerating a process that begins with the collection and assessment of plasma samples and clinical information from 40 healthy controls and 73 cancer patients.
Upon the performance of a qualitative Polymerase Chain Reaction (qPCR) using two sets of primers that facilitate the amplification of both long and short segments, the DNA integrity of the samples was calculated on the basis of the ratio of the long fragments to that of the short ones.The findings of this test as elaborated by the article made it sufficient to conclude that the Circulating Cell-free DNA is an effective molecular maker for which gastric cancer progression can be assessed and predicted. On the same breath, it is prudent to acknowledge Oncotarget’s immense effort to sensitize, educate, and proffer insights to the public regarding tumours and cancers. Their remarkable articles are certainly an exemplification of some of the great breakthroughs that have been made in the medical realm.